PETVIVO HOLDINGS, INC. ANNOUNCES CLOSE OF PURCHASE OPTION TIED TO SERIES B CONVERTIBLE PREFERRED STOCK OFFERING

Rhea-AI Summary

PetVivo Holdings (OTCQB: PETV) has successfully completed its $5 million Series B Convertible Preferred Stock offering with the final $1 million purchase option exercise. The Series B shares are priced at $1.00 per share with a 1:1 conversion ratio to common stock.

The funding will support the commercialization of two key products: SPRYNG®, an injectable veterinary device for joint pain management, and PrecisePRP®, an off-the-shelf platelet-rich plasma product for veterinary use. PrecisePRP® offers consistent dosing with 4 billion platelets per vial and eliminates the need for blood draws or centrifugation.

Positive

• Successful completion of $5 million equity financing through Series B Convertible Preferred Stock offering
• Development of innovative veterinary medical products addressing significant market needs
• PrecisePRP offers unique advantages over existing PRP kits with standardized dosing and off-the-shelf convenience
• Strong investor confidence demonstrated through full exercise of purchase option

Negative

• Potential dilution for existing shareholders through conversion of preferred stock
• Trading on OTCQB market rather than major exchange
• Shares not registered under Securities Act, limiting transferability

MINNEAPOLIS, June 24, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW) and its wholly-owned subsidiary PetVivo Animal Health, Inc. (collectively "PetVivo" or the “Company”) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for horses, dogs and other companion animals announced today that the Company has recently received One Million Dollars ($1,000,000) pursuant to the full exercise of the remaining Shares offered in a purchase option (“Purchase Option”) granted to the investor as part of an offering to receive Five Million Dollars ($5,000,000) of equity financing in exchange for Five Million shares of Series B Convertible Preferred Stock (“Shares”) (the “Offering”); pursuant to the Offering, the purchase price for one (1) Share of Series B Convertible Preferred Stock is One Dollar ($1.00) and the conversion rate is one (1) Share of Series B Convertible Preferred Stock for one (1) share of Company common stock. The Company has previously received an aggregate total of Four Million Dollars ($4,000,000) of the Offering prior to the current Purchase Option exercise. The exercise of the remaining One Million Dollars ($1,000,000) of the Purchase Option completes the issuance of all Shares allowed and thereby closes the Purchase Option of the Offering.

The proceeds from this Offering are earmarked to assist the Company in the commercialization of its signature products, SPRYNG^® with OsteoCushion^® Technology and Precise PRP^®. Spryng is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.

PrecisePRP is a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians. PrecisePRP is a leucoreduced, allogeneic, pooled, freeze-dried PRP intended to provide a species-specific source of concentrated platelets in plasma for intra-articular administration in dogs and horses. Unlike any PRP mechanical kits currently on the market, PrecisePRP^™ does not require a blood draw or centrifugation making it a truly off-the-shelf product that is easy and convenient. Perhaps more important is the uniformity and consistency that PrecisePRP^® guarantees. Each vial of PrecisePRP^® contains a consistent dose of 4 billion platelets per vial at a concentration of Five Hundred Thousand (500,000) platelets per microliter and is leucoreduced with less than One Thousand Five Hundred (1500) white blood cells per microliter.

“We are pleased to announce the successful completion of the $5 million equity financing through the full exercise of the remaining shares under the Purchase Option. The additional $1 million investment reflects continued confidence by investors and our shareholders in our vision and growth strategy. This funding enables us to further accelerate the development and commercialization of our innovative portfolio of products, including Spryng and PrecisePRP, thereby enhancing our ability to deliver impactful solutions that improve the lives of animals and their caregivers.”

For more information about PetVivo Holdings, Inc. please contact info1@petvivo.com or visit https://petvivo.com/ and https://www.sprynghealth.com.

No Offer or Solicitation

Nothing contained herein shall constitute an offer to sell or the solicitation of an offer to buy any security. The shares of Series B Convertible Preferred Stock (“Shares”) were offered and sold to persons reasonably believed to be qualified accredited investors pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The Shares have not been and will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCQB: PETV; OTCPINK: PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.

PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead products SPRYNG^™ with OsteoCushion^™ technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale.

CONTACT:

John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216

Forward-Looking Statements:

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024, and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

FAQ

What is the total value of PetVivo's (PETV) recent Series B Convertible Preferred Stock offering?

PetVivo completed a $5 million Series B Convertible Preferred Stock offering, with the final $1 million received through a purchase option exercise.

What is the conversion rate for PetVivo's Series B Convertible Preferred Stock?

The conversion rate is 1:1, meaning one share of Series B Convertible Preferred Stock converts to one share of company common stock.

What will PetVivo (PETV) use the funding for?

The proceeds will fund the commercialization of SPRYNG® with OsteoCushion® Technology and PrecisePRP®, their signature veterinary medical products.

What makes PetVivo's PrecisePRP product unique in the market?

PrecisePRP is a first-in-class off-the-shelf PRP product that doesn't require blood draws or centrifugation, offering consistent dosing of 4 billion platelets per vial.

How many platelets does each vial of PetVivo's PrecisePRP contain?

Each vial contains 4 billion platelets at a concentration of 500,000 platelets per microliter, with less than 1,500 white blood cells per microliter.